Skip to main content
Top
Published in: Discover Oncology 4/2013

01-08-2013 | Original Paper

RNA Sequencing of MCF-7 Breast Cancer Cells Identifies Novel Estrogen-Responsive Genes with Functional Estrogen Receptor-Binding Sites in the Vicinity of Their Transcription Start Sites

Authors: Ryonosuke Yamaga, Kazuhiro Ikeda, Kuniko Horie-Inoue, Yasuyoshi Ouchi, Yutaka Suzuki, Satoshi Inoue

Published in: Discover Oncology | Issue 4/2013

Login to get access

Abstract

Estrogen receptor α (ERα) is a key transcription factor in breast cancer, which plays an essential role in the pathophysiology of the disease by regulating the expression of various target genes. In the present study, we performed deep RNA sequencing (RNA-seq) as an unbiased high-throughput technique for comprehensive transcriptome analysis in ERα-positive human breast cancer MCF-7 cells, to facilitate the elucidation of ERα regulatory gene networks. From the 17,336 mapped RefSeq genes from the sequenced fragments of the cell samples treated with estrogen time dependently, substantial numbers of sequence reads were observed in 3,386 genes (>100 tags per million reads per sample at any of the six time points studied). ERα occupancy within and in the proximal regions of the genes (<10-kb upstream and downstream regions) was significantly enriched in the subgroup of the 3,386 genes compared to the whole 17,336 RefSeq genes. Of the 3,386 genes, we focused on 29 genes, which included ERα occupancy adjacent to their transcription start sites and whose expression was estrogen dependently altered by >3-fold. Knockdown studies using siRNAs specific to the 29 genes validated that prototypic ERα targets V-myc myelocytomatosis viral oncogene homolog and cyclin D1 promote both proliferation and migration of MCF-7 cells and further identified novel candidate ERα targets EIF3A and tumor protein D52-like 1, which will also facilitate the proliferation or migration of MCF-7 cells. Taken together, the present findings provide a valuable dataset that will elucidate ERα regulatory mechanisms in breast cancer biology, based on the integrative analysis of RNA-seq combined with the genome-wide information for ERα occupancy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedCrossRef
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef
3.
4.
go back to reference Colditz GA (1998) Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 90:814–823PubMedCrossRef Colditz GA (1998) Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 90:814–823PubMedCrossRef
5.
go back to reference Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29:2905–2919PubMedCrossRef Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29:2905–2919PubMedCrossRef
6.
go back to reference Mo R, Tony Zhu Y, Zhang Z, Rao SM, Zhu YJ (2007) GAS6 is an estrogen-inducible gene in mammary epithelial cells. Biochem Biophys Res Commun 353:189–194PubMedCrossRef Mo R, Tony Zhu Y, Zhang Z, Rao SM, Zhu YJ (2007) GAS6 is an estrogen-inducible gene in mammary epithelial cells. Biochem Biophys Res Commun 353:189–194PubMedCrossRef
7.
go back to reference Inoue A, Omoto Y, Yamaguchi Y, Kiyama R, Hayashi SI (2004) Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol 32:649–661PubMedCrossRef Inoue A, Omoto Y, Yamaguchi Y, Kiyama R, Hayashi SI (2004) Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol 32:649–661PubMedCrossRef
8.
go back to reference Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10:57–63PubMedCrossRef Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10:57–63PubMedCrossRef
9.
go back to reference Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P, Koenig J, Lappe M, Kuss AW, Garshasbi M, Bertram L, Trappe K, Werber M, Herrmann BG, Zatloukal K, Lehrach H, Schweiger MR (2010) Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 5(12):e15661PubMedCrossRef Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P, Koenig J, Lappe M, Kuss AW, Garshasbi M, Bertram L, Trappe K, Werber M, Herrmann BG, Zatloukal K, Lehrach H, Schweiger MR (2010) Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 5(12):e15661PubMedCrossRef
10.
go back to reference Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordóñez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T, Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A, Mudie LJ, Ning Z, Royce T, Schulz-Trieglaff OB, Spiridou A, Stebbings LA, Szajkowski L, Teague J, Williamson D, Chin L, Ross MT, Campbell PJ, Bentley DR, Futreal PA, Stratton MR (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191–196PubMedCrossRef Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordóñez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T, Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A, Mudie LJ, Ning Z, Royce T, Schulz-Trieglaff OB, Spiridou A, Stebbings LA, Szajkowski L, Teague J, Williamson D, Chin L, Ross MT, Campbell PJ, Bentley DR, Futreal PA, Stratton MR (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191–196PubMedCrossRef
11.
go back to reference Huang Q, Lin B, Liu H, Ma X, Mo F, Yu W, Li L, Li H, Tian T, Wu D, Shen F, Xing J, Chen ZN (2011) RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS One 6(10):e26168PubMedCrossRef Huang Q, Lin B, Liu H, Ma X, Mo F, Yu W, Li L, Li H, Tian T, Wu D, Shen F, Xing J, Chen ZN (2011) RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS One 6(10):e26168PubMedCrossRef
12.
go back to reference Carraro DM, Ferreira EN, de Campos MG, Puga RD, Abrantes EF, Trapé AP, Eckhardt BL, Nunes DN, Brentani MM, Arap W, Pasqualini R, Brentani H, Dias-Neto E, Brentani RR (2011) Poly (A) + transcriptome assessment of ERBB2-induced alterations in breast cell lines. PLoS One 6(6):e21022PubMedCrossRef Carraro DM, Ferreira EN, de Campos MG, Puga RD, Abrantes EF, Trapé AP, Eckhardt BL, Nunes DN, Brentani MM, Arap W, Pasqualini R, Brentani H, Dias-Neto E, Brentani RR (2011) Poly (A) + transcriptome assessment of ERBB2-induced alterations in breast cell lines. PLoS One 6(6):e21022PubMedCrossRef
13.
go back to reference Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38:1289–1297PubMedCrossRef Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38:1289–1297PubMedCrossRef
14.
go back to reference Deschênes J, Bourdeau V, White JH, Mader S (2007) Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20 kb of upstream flanking sequences. J Biol Chem 282:17335–17339PubMedCrossRef Deschênes J, Bourdeau V, White JH, Mader S (2007) Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20 kb of upstream flanking sequences. J Biol Chem 282:17335–17339PubMedCrossRef
15.
go back to reference Nass SJ, Dickson RB (1997) Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 44:1–22PubMedCrossRef Nass SJ, Dickson RB (1997) Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 44:1–22PubMedCrossRef
16.
go back to reference Liao DJ, Dickson RB (2000) c-Myc in breast cancer. EndocrRelat Cancer 7:143–164CrossRef Liao DJ, Dickson RB (2000) c-Myc in breast cancer. EndocrRelat Cancer 7:143–164CrossRef
17.
go back to reference Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T, Ijichi N, Ouchi Y, Shirahige K, Aburatani H, Inoue S (2007) Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26:4453–4463PubMedCrossRef Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T, Ijichi N, Ouchi Y, Shirahige K, Aburatani H, Inoue S (2007) Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26:4453–4463PubMedCrossRef
18.
go back to reference Ueyama K, Ikeda K, Sato W, Nakasato N, Horie-Inoue K, Takeda S, Inoue S (2010) Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth. Cancer Gene Ther 17:624–632PubMedCrossRef Ueyama K, Ikeda K, Sato W, Nakasato N, Horie-Inoue K, Takeda S, Inoue S (2010) Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth. Cancer Gene Ther 17:624–632PubMedCrossRef
19.
go back to reference Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M (1997) Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 236:140–145PubMedCrossRef Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M (1997) Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 236:140–145PubMedCrossRef
20.
go back to reference Wang YH, Liu S, Zhang G, Zhou CQ, Zhu HX, Zhou XB, Quan LP, Bai JF, Xu NZ (2005) Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 7:R220–R228PubMedCrossRef Wang YH, Liu S, Zhang G, Zhou CQ, Zhu HX, Zhou XB, Quan LP, Bai JF, Xu NZ (2005) Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 7:R220–R228PubMedCrossRef
21.
go back to reference Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23:4215–4224PubMedCrossRef Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23:4215–4224PubMedCrossRef
23.
go back to reference Aaltonen K, Amini RM, Landberg G, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H, Blomqvist C (2009) Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat 113:75–82PubMedCrossRef Aaltonen K, Amini RM, Landberg G, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H, Blomqvist C (2009) Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat 113:75–82PubMedCrossRef
24.
go back to reference Dong Z, Liu Z, Cui P, Pincheira R, Yang Y, Liu J, Zhang JT (2009) Role of eIF3a in regulating cell cycle progression. Exp Cell Res 315:1889–1894PubMedCrossRef Dong Z, Liu Z, Cui P, Pincheira R, Yang Y, Liu J, Zhang JT (2009) Role of eIF3a in regulating cell cycle progression. Exp Cell Res 315:1889–1894PubMedCrossRef
25.
go back to reference Saletta F, SuryoRahmanto Y, Richardson DR (2010) The translational regulator eIF3a: the tricky eIF3 subunit! Biochim Biophys Acta 1806:275–286PubMed Saletta F, SuryoRahmanto Y, Richardson DR (2010) The translational regulator eIF3a: the tricky eIF3 subunit! Biochim Biophys Acta 1806:275–286PubMed
26.
go back to reference Olson JE, Wang X, Goode EL, Pankratz VS, Fredericksen ZS, Vierkant RA, Pharoah PD, Cerhan JR, Couch FJ (2010) Variation in genes required for normal mitosis and risk of breast cancer. Breast Cancer Res Treat 119:423–430PubMedCrossRef Olson JE, Wang X, Goode EL, Pankratz VS, Fredericksen ZS, Vierkant RA, Pharoah PD, Cerhan JR, Couch FJ (2010) Variation in genes required for normal mitosis and risk of breast cancer. Breast Cancer Res Treat 119:423–430PubMedCrossRef
27.
go back to reference Boutros R, Bailey AM, Wilson SH, Byrne JA (2003) Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins. J Mol Biol 332:675–687PubMedCrossRef Boutros R, Bailey AM, Wilson SH, Byrne JA (2003) Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins. J Mol Biol 332:675–687PubMedCrossRef
28.
go back to reference Boutros R, Byrne JA (2005) D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells. Exp Cell Res 310:152–165PubMedCrossRef Boutros R, Byrne JA (2005) D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells. Exp Cell Res 310:152–165PubMedCrossRef
29.
go back to reference Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, Gaddis S, Shi T, Horvath S, Sahin A, Aldaz CM (2007) Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 5:881–890PubMedCrossRef Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, Gaddis S, Shi T, Horvath S, Sahin A, Aldaz CM (2007) Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 5:881–890PubMedCrossRef
30.
go back to reference Zacchi P, Stenmark H, Parton RG, Orioli D, Lim F, Giner A, Mellman I, Zerial M, Murphy C (1998) Rab17 regulates membrane trafficking through apical recycling endosomes in polarized epithelial cells. J Cell Biol 140:1039–1053PubMedCrossRef Zacchi P, Stenmark H, Parton RG, Orioli D, Lim F, Giner A, Mellman I, Zerial M, Murphy C (1998) Rab17 regulates membrane trafficking through apical recycling endosomes in polarized epithelial cells. J Cell Biol 140:1039–1053PubMedCrossRef
31.
go back to reference Palmieri D, Bouadis A, Ronchetti R, Merino MJ, Steeg PS (2006) Rab11a differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells. Breast Cancer Res Treat 100:127–137PubMedCrossRef Palmieri D, Bouadis A, Ronchetti R, Merino MJ, Steeg PS (2006) Rab11a differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells. Breast Cancer Res Treat 100:127–137PubMedCrossRef
32.
go back to reference Cheng JM, Volk L, Janaki DK, Vyakaranam S, Ran S, Rao KA (2010) Tumor suppressor function of Rab25 in triple-negative breast cancer. Int J Cancer 126:2799–2812PubMed Cheng JM, Volk L, Janaki DK, Vyakaranam S, Ran S, Rao KA (2010) Tumor suppressor function of Rab25 in triple-negative breast cancer. Int J Cancer 126:2799–2812PubMed
33.
go back to reference Hendrix A, Maynard D, Pauwels P, Braems G, Denys H, Van den Broecke R, Lambert J, Van Belle S, Cocquyt V, Gespach C, Bracke M, Seabra MC, Gahl WA, De Wever O, Westbroek W (2010) Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst 102:866–880PubMedCrossRef Hendrix A, Maynard D, Pauwels P, Braems G, Denys H, Van den Broecke R, Lambert J, Van Belle S, Cocquyt V, Gespach C, Bracke M, Seabra MC, Gahl WA, De Wever O, Westbroek W (2010) Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst 102:866–880PubMedCrossRef
34.
go back to reference Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562–4574PubMedCrossRef Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562–4574PubMedCrossRef
35.
go back to reference Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, Hayashi S, Fujii Y, Iwase H, Yamashita H (2007) Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol 37:575–582PubMedCrossRef Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, Hayashi S, Fujii Y, Iwase H, Yamashita H (2007) Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol 37:575–582PubMedCrossRef
36.
go back to reference Qin C, Singh P, Safe S (1999) Transcriptional activation of insulin-like growth factor-binding protein-4 by 17beta-estradiol in MCF-7 cells: role of estrogen receptor-Sp1 complexes. Endocrinology 140:2501–2508PubMedCrossRef Qin C, Singh P, Safe S (1999) Transcriptional activation of insulin-like growth factor-binding protein-4 by 17beta-estradiol in MCF-7 cells: role of estrogen receptor-Sp1 complexes. Endocrinology 140:2501–2508PubMedCrossRef
37.
go back to reference Wang C, Yu J, Kallen CB (2008) Two estrogen response element sequences near the PCNA gene are not responsible for its estrogen-enhanced expression in MCF7 cells. PLoS One 3:e3523PubMedCrossRef Wang C, Yu J, Kallen CB (2008) Two estrogen response element sequences near the PCNA gene are not responsible for its estrogen-enhanced expression in MCF7 cells. PLoS One 3:e3523PubMedCrossRef
38.
go back to reference Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE, Venter DJ (2002) Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res 62:1289–1295PubMed Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE, Venter DJ (2002) Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res 62:1289–1295PubMed
39.
go back to reference Laganière J, Deblois G, Giguère V (2005) Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. Mol Endocrinol 19:1584–1592PubMedCrossRef Laganière J, Deblois G, Giguère V (2005) Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. Mol Endocrinol 19:1584–1592PubMedCrossRef
40.
go back to reference Jin C, Rajabi H, Pitroda S, Li A, Kharbanda A, Weichselbaum R, Kufe D (2012) Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One 7:e39432PubMedCrossRef Jin C, Rajabi H, Pitroda S, Li A, Kharbanda A, Weichselbaum R, Kufe D (2012) Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One 7:e39432PubMedCrossRef
41.
go back to reference Augereau P, Badia E, Fuentes M, Rabenoelina F, Corniou M, Derocq D, Balaguer P, Cavailles V (2006) Transcriptional regulation of the human NRIP1/RIP140 gene by estrogen is modulated by dioxin signalling. Mol Pharmacol 69:1338–1346PubMedCrossRef Augereau P, Badia E, Fuentes M, Rabenoelina F, Corniou M, Derocq D, Balaguer P, Cavailles V (2006) Transcriptional regulation of the human NRIP1/RIP140 gene by estrogen is modulated by dioxin signalling. Mol Pharmacol 69:1338–1346PubMedCrossRef
42.
go back to reference Guérin M, Sheng ZM, Andrieu N, Riou G (1990) Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 5:131–135PubMed Guérin M, Sheng ZM, Andrieu N, Riou G (1990) Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 5:131–135PubMed
Metadata
Title
RNA Sequencing of MCF-7 Breast Cancer Cells Identifies Novel Estrogen-Responsive Genes with Functional Estrogen Receptor-Binding Sites in the Vicinity of Their Transcription Start Sites
Authors
Ryonosuke Yamaga
Kazuhiro Ikeda
Kuniko Horie-Inoue
Yasuyoshi Ouchi
Yutaka Suzuki
Satoshi Inoue
Publication date
01-08-2013
Publisher
Springer-Verlag
Published in
Discover Oncology / Issue 4/2013
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-013-0140-3

Other articles of this Issue 4/2013

Discover Oncology 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.